Mavyret (glecaprevir and pibrentasvir)

When is Mavyret contraindicated?

Mavyret is contraindicated in patients with severe hepatic impairment. Additionally, Mavyret is contraindicated for use with atazanavir and rifampin.

The following chart provides information regarding additional medications that can have potential interactions with Mavyret. This table is not all inclusive.

Drug Class	Specific Drugs Within Class Contraindicated with Mavyret
Antiarrhythmics	Digoxin
Anticoagulants	Dabigatran
Anticonvulsants	Carbamazepine
Antimycobacterials	Rifampin
Ethinyl Estradiol-Containing Products	Ethinyl estradiol-containg medication such as combined oral contraceptives
Herbal Supplements	St. Johns’ wort (Hypericum perforatum)
HIV-Antiviral Agents	Atazanavir, Darunavir, Lopinavir, Ritonavir, Efavirenz
HMG-CoA Reductase Inhibitors	Atorvastatin, Lovastatin, Simvastatin, Pravastatin, Rosuvastatin, Fluvastatin, Pitavastatin
Immunosupporessants	Cyclosporine

Last Updated: October 2017

What is the dosage for Mavyret? What types of adverse reactions were reported when taking Mavyret?

References

"FDA approves Mavyret for Hepatitis C." FDA.gov. U.S. Food & Drug Administration. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm570038.htm. Retrieved October 6, 2017.

"Highlights of Prescribing Information." Rxabbvie.com. AbbVie Inc., http://www.rxabbvie.com/pdf/mavyret_pi.pdf. Retrieved October 6, 2017.

"Mavyret Product Summary." Mavyret.com. AbbVie Inc., https://www.mavyret.com/content/dam/abbvie-mavyret-brand/product-summary.pdf. Retrieved October 6, 2017.

"Introducing MavyRet." Mavyret.com. AbbVie Inc., www.mavyret.com. Retrieved October 6, 2017.